Cholesterol reduction yields clinical benefits: meta-analysis including recent trials

https://doi.org/10.1016/j.clinthera.2007.05.012Get rights and content

Abstract

Background:

Previous meta-analyses reported by Gould et al found significant decreases of 15% in the risk for coronary heart disease (CHD)-related mortality and 11 % in risk for all-cause mortality per decrease of 10% in total cholesterol (TC) level.

Objective:

To evaluate the effects of reducing cholesterol on clinical events after including data from recent clinical trials.

Methods:

Using a literature search (MeSH key terms, including: bezafibrate, coronary disease, efficacy, gemfibrozil, hydroxymethylglutaryl-CoA reductase inhibitors, hypercholesterolemia, niacin [nicotinic acids], randomized controlled trials, and treatment outcome; years: 1999–2005), we identified trials published in English that assessed the effects of lipid-modifying therapies on CHD end points, including CHD-related death, myocardial infarction, and angina pectoris. We also included all studies from the previously published meta-analysis. Using the same analytic approach as previously, we determined the effects of net absolute reductions (1 mmol/L [38.7 mg/dL]) in TC and low-density lipoprotein cholesterol (LDL-C) on the relative risks (RRs) for all-cause mortality, CHD-related mortality, any CHD event (mortality or nonfatal myocardial infarction), and non-CHD-related mortality.

Results:

We included 62 studies involving 216,616 patients, including 126,474 from 24 randomized controlled trials the findings of which were published since the previous meta-analysis (1998). Among all patients, for every 1-mmol/L decrease in TC, there was a 17.5 reduction in RR for all-cause mortality; 24.5 %, for CHD-related mortality; and 29.5% for any CHD event. Corresponding reductions for every 1-mmol/L decrease in LDL-C were 15.6%, 28.0%, and 26.6%, respectively. Similar relationships were observed in patients without CHD. No significant relationship was found between lipid reduction and non-CHD-related mortality risk.

Conclusions:

The results from the present analysis support conclusions from previous meta-analyses that cholesterol lowering is clinically beneficial in patients with CHD or at elevated CHD risk. These results also support the previous finding that non-CHD-related mortality is unrelated to lipid reductions.

References (116)

  • WattsG.F. et al.

    Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

    Lancet

    (1992)
  • SahniR. et al.

    Prevention of restenosis by lovastatin after successful coronary an gioplasty

    Am Heart J.

    (1991)
  • HeadyJ.A et al.

    WHO clofibrate/cholesterol trial: Clarifications

    Lancet

    (1992)
  • DorrA.E. et al.

    Colestipol hydrochloride in hypercholesterolemic patients effect on serum cholesterol and mortality

    J Chronic Dis.

    (1978)
  • HjermannI. et al.

    Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men

    Lancet

    (1981)
  • PearsonT.A. et al.

    A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial

  • GagneC. et al.

    Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

    Am J Cardiol.

    (2002)
  • World Health Organization (WHO)

    The World Health Report: 2003; shaping the future. [WHO Web site]

    (2003)
  • World Health Organization (WHO)

    The World Health Report: 2002; reducing risks, promoting healthy life [WHO Web site]

    (2002)
  • CollinsR. et al.

    MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial

    Lancet

    (2003)
  • CannonC.P. et al.

    Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes

    N EngI J Med.

    (2004)
  • NissenS.E. et al.

    Statin therapy, LDLcholesterol, C-reactive protein, and coronary artery disease

    N Engl J Med.

    (2005)
  • LaRosaJ.C. et al.

    Intensive lipid lowering with atorvastatin in patients with stable coronary disease

    N Engl J Med.

    (2005)
  • CollinsR. et al.

    Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

    Lancet

    (2004)
  • NissenS.E. et al.

    Effect of intensive compared with moderate lipid-lowering therapy on progression of coro nary atherosclerosis: A randomized controlled trial

    JAMA

    (2004)
  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

    Circulation

    (2002)
  • FusterV. et al.

    Acute coronary syndromes: Biology

    Lancet

    (1999)
  • TherouxP. et al.

    Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction

    Circulation

    (1998)
  • LibbyP.

    Molecular bases of the acute coronary syndromes

    Circulation

    (1995)
  • BrownG. et al.

    What benefit can be derived from treating normocholesterolemic patients with coronary artery disease?

    Am J Cardiol

    (1995)
  • GouldA.L. et al.

    Cholesterol reduction yields clinical benefit: Impact of statin trials

    Circulation

    (1998)
  • GouldA.L. et al.

    Cholesterol reduction yields clinical benefit. A new look at old data

    Circulation

    (1995)
  • BaigentC. et al.

    Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366:1358]

    Lancet

    (2005)
  • RidkerP.M. et al.

    C-reactive protein levels and outcomes after statin therapy

    N Engl J Med.

    (2005)
  • GrundyS.M. et al.

    Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004; 110:763]

    Circulation

    (2004)
  • DownsJ.R. et al.

    Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

    JAMA

    (1998)
  • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group

    N Engl J Med.

    (1998)
  • Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: Do stopped trials contribute to overall knowledge?

    Ital Heart J

    (2000)
  • SerruysP.W. et al.

    Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial

    JAMA

    (2002)
  • PedersenT.R. et al.

    High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial

    JAMA

    (2005)
  • de LemosJ.A. et al.

    Early intensive vs a delayed conser vative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial

    JAMA

    (2004)
  • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial

    Lancet.

    (2002)
  • The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT LLT)

    JAMA

    (2002)
  • KoizumiJ. et al.

    Effect of pravastatin-induced LDL cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease studypravastatin atherosclerosis trial (Holicos-PAT)

    J Atheroscler Thromb.

    (2002)
  • The Post Coronary Artery Bypass Graft Trial Investigators

    The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

    N Engl J Med.

    (1997)
  • BestehornH.P. et al.

    The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS)

    Eur Heart J.

    (1997)
  • Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study

    Circulation

    (2000)
  • RubinsH.B. et al.

    Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol

    N Engl J Med.

    (1999)
  • KeechA. et al.

    Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial

    Lancet

    (2005)
  • Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclero sis Intervention Study, a randomised study

    Lancet

    (2001)
  • Cited by (120)

    • The joint effect between fetal growth and health behaviors on the risk of cardiovascular diseases in young adulthood

      2023, Annals of Epidemiology
      Citation Excerpt :

      Studies showed high levels of oxidative stress [23] and inflammation [24] in these neonates. Alterations in fetal epigenomics [25], lipid profile [26], and gut microbiota [28] in these infants may further contribute to an increased risk of CVDs later in life. Furthermore, birth weight-for-gestational age was associated with DNA methylation at birth and in childhood [27].

    View all citing articles on Scopus
    View full text